Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2025-06-04 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于股票交易严重异常波动暨风险提示的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company regarding serious abnormal fluctuations in its stock trading and associated risk warnings. It references the company's 2024 Annual Report but does not contain the report itself or detailed financial statements. The document discusses stock price volatility, risk factors, shareholder changes, and regulatory compliance, typical of a regulatory announcement to inform investors about trading risks and company status. The document length is 3872 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial data or comprehensive analysis that would classify it as an Annual Report (10-K) or Interim Report (IR). It is not a certification or officer attestation document, so it is not Regulatory Filings (RNS) by the certification rule. The content fits best with a Regulatory Filings (RNS) category as it is a regulatory disclosure about stock trading abnormalities and risk warnings without being a full financial report or other specific filing type.
2025-06-04 Chinese
关于股票交易异常波动暨风险提示的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company regarding abnormal stock price fluctuations and associated risk warnings. It references the company's 2024 Annual Report but does not contain the report itself or detailed financial statements. The document discusses stock trading risks, shareholder changes, and regulatory compliance related to stock trading and potential delisting risks. It is relatively short (3344 characters) and serves as a risk disclosure and stock trading abnormality notice rather than a full financial report or earnings release. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-05-28 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock trading fluctuations and related risk disclosures. It references the company's 2024 Annual Report but does not contain the report itself or detailed financial data. The document discusses stock trading warnings, shareholder changes, and risk factors, typical of a regulatory announcement. The length is under 5,000 characters and it primarily serves to inform investors about stock trading risks and shareholder changes, not to present financial results or detailed management discussion. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Annual Report or other detailed financial report.
2025-05-25 Chinese
关于受让方海南雅亿共赢科技合伙企业（有限合伙）完成工商变更登记暨公司控制权拟发生变更的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of a business registration change and the potential change in control of the company due to a share transfer agreement. It details changes in the registered capital and partners of the acquiring entity, and mentions the impact on the company's controlling shareholder and actual controller. There are no financial statements, audit information, or detailed financial performance data. The document is a regulatory announcement about a corporate control change and related business registration updates, not a full report or financial filing. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (1811 characters), and it is an announcement rather than a report itself.
2025-05-23 Chinese
简式权益变动报告书（蔡南桂、唐霖）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report". It details the change in shareholding of key shareholders (蔡南桂 and 唐霖) in the company 赛隆药业集团股份有限公司, including the transfer of shares to 海南雅亿, the shareholding percentages before and after the transaction, the terms of the share transfer agreement, payment details, and related commitments and guarantees. The document references compliance with Chinese securities laws and Shenzhen Stock Exchange regulations. It is a detailed disclosure of a significant change in share ownership and control of the company, including the relinquishment of voting rights by the sellers. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is not an annual report, earnings release, or management report, nor is it a proxy solicitation or voting result announcement. It is a comprehensive equity change disclosure filing.
2025-05-23 Chinese
详式权益变动报告书（海南雅亿）
Major Shareholding Notification Classification · 95% confidence The document is titled "详式权益变动报告书" which translates to "Detailed Equity Change Report". It is issued by a shareholder (海南雅亿共赢科技合伙企业) disclosing a significant change in shareholding in 赛隆药业集团股份有限公司, including detailed information about the share transfer agreement, shareholding percentages before and after the transaction, the purpose of the equity change, and the legal and procedural compliance related to the transaction. The document references relevant Chinese securities laws and regulations governing equity changes and disclosures. It is a comprehensive report on a major shareholding change, including the acquisition of control of the company by the new shareholder. This fits the definition of "Major Shareholding Notification (Code: MRQ)" which covers notifications of changes in significant share ownership levels crossing thresholds. The document is lengthy (15,000 characters) and contains detailed substantive information about the shareholding change, not just an announcement or a brief notice. Therefore, the correct classification is MRQ with high confidence.
2025-05-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.